menu
    • menu
    [{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.28999999999999998,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"WuXi STA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ WuXi STA","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ WuXi STA"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0.93999999999999995,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.93999999999999995,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Biogen"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"InnoCare Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Incyte Corporation \/ InnoCare","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ InnoCare"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Immunology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"China International Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Orelabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ China International Capital","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare Pharma \/ China International Capital"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ICP-248","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"InnoCare Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Orelabrutinib

    Menu

    Orelabrutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ICP-248,Orelabrutinib

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            InnoCare Receives Approval for ICP-248 Clinical Trial with Orelabrutinib in China

                            Details : ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which is being evaluated in combination with orelabrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma.

                            Brand Name : ICP-248

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 12, 2024

                            Lead Product(s) : ICP-248,Orelabrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatmen...

                            Details : Hibruka (orelabrutinib) is a highly selective BTK inhibitor developed for the treatment of cancers and autoimmune diseases. Currently under development for the treatment of primary immune thrombocytopenia (ITP) in China.

                            Brand Name : Hibruka

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 26, 2023

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatm...

                            Details : Hibruka (orelabrutinib) is a highly selective BTK inhibitor developed for the treatment of cancers and autoimmune diseases. Currently under development for the treatment of R/R MZL in China.

                            Brand Name : Hibruka

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 19, 2023

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published by American Journal of Hematology

                            Details : Hibruka (orelabrutinib) is a highly selective BTK inhibitor developed for the treatment of cancers and autoimmune diseases. Currently under development for for the treatment of MS, SLE, ITP and NMOSD in China.

                            Brand Name : Hibruka

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 07, 2023

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orelabrutinib,Tafasitamab,Lenalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasita...

                            Details : Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. Tafasitamab is a humanized Fc-modified CD19 targeting immunotherapy.

                            Brand Name : Hibruka

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2022

                            Lead Product(s) : Orelabrutinib,Tafasitamab,Lenalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore

                            Details : Hibruka (orelabrutinib) is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. As a highly selective BTK inhibitor, orelabrutinib has demonstrated good efficacy and safety in the treatment of R/R M...

                            Brand Name : Hibruka

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 22, 2022

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : China International Capital

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China

                            Details : InnoCare will use the net proceeds from the STAR offering to fund its drug research and development of ICP-022 (orelabrutinib), drug R&D platform upgrade, marketing network upgrade, information technology upgrade and working capital projects.

                            Brand Name : ICP-022

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 20, 2022

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : China International Capital

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory...

                            Details : ICP-022 (orelabrutinib) is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases, was well tolerated with a safety profile in the patients with MZL.

                            Brand Name : ICP-022

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 12, 2022

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Latest Data of InnoCare’s Orelabrutinib for the Treatment of SLE Presented at LBA Session of EULAR 2022

                            Details : The study randomized 60 patients with 55 patients who completed 12-week treatment. Baseline disease characteristics were generally balanced across treatment groups. ICP-022 (orelabrutinib) was generally well tolerated in patients with SLE.

                            Brand Name : ICP-022

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 06, 2022

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            InnoCare Pharma

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting

                            Details : ICP-022 (orelabrutinib) is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. The plasma exposure of orelabrutinib (AUC and Cmax) was proportionally increased with doses.

                            Brand Name : ICP-022

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 06, 2022

                            Lead Product(s) : Orelabrutinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth